Abstract:The development of targeted therapies has revolutionized the treatment of non-small cell lung cancer. Interrogating the status of driver mutations has become routine practice. In this study, we applied next-generation sequencing to investigate the association between molecular signature and clinical benefit. We performed capture-based targeted ultra-deep sequencing on 204 samples obtained from NSCLC patients at a single center, including 93 FFPE, 70 fresh tissue and 41 plasma samples. One hundred and twenty two samples were subjected to a panel consisting of 8 driver genes; 50 samples were subjected to a 56-gene panel. The remaining 32 samples were subject to a 168 gene panel. In 159 TKI-naïve patients, driver mutation was identified in 95.2% of (79/83) patients using the 8-gene panel; among them, 65.1% (54/83) carried EGFR mutations. Larger panels identified mutations in 68.1% of patients; 21% carried mutations other than driver mutations. Treatment-naïve patients were primarily subject to the 8-gene panel; in contrast, patients progressed on chemotherapy were subject to larger panels. Seventy-two percent of patients (80/111) undergone matched targeted therapy (MTT) according to sequencing results had a significantly longer PFS than 29 patients who chose chemotherapies despite the fact of harboring driver (p=4.58x10-4 HR=0.342, 95% CI: 0.158, 0.74). Next, we investigated whether the number of EGFR mutations a patient carries and the presence of concurrence EGFR amplification have an effect on PFS. Our data revealed that both parameters are not associated with PFS. Among 46 patients receiving chemotherapy, patients with KRAS mutations were associated with a shorter PFS, 133 days vs 207 days (p= 0.073, HR=2.06 95% CI; 0.791, 5.36). For TKI-naïve patients, primary tumor tissue was collected from 86 patients and tumor tissue from metastatic lymph nodes was collected from 35 patients. Interestingly, we observed that lymph node samples had a higher maximum mutation allelic fraction (MAF) than primary lung tumor samples in patients with distance metastasis, especially with visceral metastasis (p=0.0986); such trend was not observed in patients without distant metastasis. We also analyzed samples obtained after TKI-treatment. Among 36 TKI-treated patients, patients with visceral metastasis were more likely to harbor TP53 mutations (p=0.04), which were primarily missense mutations not loss of function mutations, primarily seen in tumorigenesis. TP53 missense mutations can potentially promote distant visceral metastasis after the development of resistance to TKIs. Our study highlighted the utility of sequencing-based screening technologies and characteristics in providing treatment guidance.

16PCOMPREHENSIVE ANALYSIS OF DRIVER MUTATIONS IN CHINESE SQUAMOUS CELL LUNG CARCINOMAS BY TARGETED NEXT-GENERATION SEQUENCING

Characterization of Driver Mutations in Chinese Non-Small Cell Lung Cancer Patients Using a Novel Targeted Sequencing Panel

Analysis of Major Known Driver Mutations and Prognosis in Resected Adenosquamous Lung Carcinomas

Validating a Targeted Next-Generation Sequencing Assay and Profiling Somatic Variants in Chinese Non-Small Cell Lung Cancer Patients

Comprehensive Investigation of Oncogenic Driver Mutations in Chinese Non-Small Cell Lung Cancer Patients.

23P Genomic Profiling of Gene Aberrations in 323 Chinese NSCLC Patients

Whole Exome Sequencing Identifies Frequent Somatic Mutations in Cell-Cell Adhesion Genes in Chinese Patients with Lung Squamous Cell Carcinoma.

Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component.

Comprehensive analysis of targetable oncogenic mutations in chinese cervical cancers

Pathogenic Germline Mutation Profile In Chinese Lung Cancers And Related-Driver Mutation Pattern.

Genomic Profiling of Driver Gene Mutations in Chinese Patients with Non-Small Cell Lung Cancer

Genetic Mutation Analysis in Small Cell Lung Cancer by a Novel NGS-Based Targeted Resequencing Gene Panel and Relation with Clinical Features

Detection and monitoring of driver mutations by next-generation sequencing in squamous cell lung cancer patient and possible predictive biomarker of third generation EGFR-tyrosine kinase inhibitors.

Exome Sequencing Identifies Somatic Mutations in Novel Driver Genes in Non-Small Cell Lung Cancer.

Comprehensive Investigation of Clinicopathologic Features, Oncogenic Driver Mutations and Immunohistochemical Markers in Peripheral Lung Squamous Cell Carcinoma.

Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival

Umbrella Study of Anticancer Agents in Chinese Patients with NSCLC.

Whole-Exome Sequencing to Identify Novel Somatic Mutations in Squamous Cell Lung Cancers

P1.01-035 A Next Generation Sequencing and Characteristics Based Model for Predict Clinical Benefits of Advanced NSCLC Patients

Preliminary Analysis of Genomic Profiling of Small Cell Lung Cancer in Chinese Population Revealed Frequent PIK3CA Hotspot Mutations.

Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients.